Regarding "recommendations for zoledronic acid treatment of patients with bone metastases" [1]

Oncologist

Volumn 10, Issue 5, 2005, Pages 304-305

  Parles, Karen ^a  

^a Lung Cancer Online Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ZOLEDRONIC ACID;

BONE CANCER; BONE METASTASIS; BONE NECROSIS; DRUG APPROVAL; HUMAN; LETTER; PRIORITY JOURNAL; SAFETY;

BONE DISEASES, METABOLIC; BONE NEOPLASMS; CLINICAL TRIALS; CREATININE; DIPHOSPHONATES; EDUCATION, MEDICAL, CONTINUING; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; KIDNEY; PRACTICE GUIDELINES;

EID: 18444417443     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-5-304     Document Type: Letter

References (6)

1. Berenson J. Recommendations for zoledronic acid treatment of patients with bone metastases. The Oncologist 2005;10:52-62.
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117.
3. Zometa (zoledronic acid) Injection: Prescribing Information (Rev: August 2004):20. Available at: http://www.pharma. us.novartis.com/product/pi/pdf/ Zometa.pdf
4. Novartis "Dear Doctor" letter: September 24, 2004. Available at: http://www.fda.gov/medwatch/SAFETY/2004/ZometaHCP.pdf
5. Steinbrook R. Commercial Support and Continuing Medical Education. N Engl J Med 2005; 352:534-535.
6. ACCME Standards for Commercial Support (September 2004). Available at: http://www.accme.org/dir_docs/doc_ upload/68b2902a-fb73-44d1-8725- 80a1504e520c_upload document.pdf